Table 2 Correlation (univariate Cox analysis) between demographic and clinical variables and survival in patients undergoing HSCT with cells from UCB and from HAPLO

From: Survival, toxicity and length of stay after haploidentical or cord blood transplantation in a Latin American center: a cross-sectional, comparative study

 

Coefficient

HR

CI

P-value

   

Inferior

Superior

 

Cellularity (TNC) in UCB

0.00

1.00

0.14

7.10

0.629

Cellularity (TNC) in HAPLO

0.00

1.00

2.72

2.72

0.961

Hospital admissions in the first year in UCB

−0.94

0.39

0.18

0.84

<0.001

Hospital admissions in the first year in HAPLO

−0.69

0.50

0.97

2.83

0.012

Male gender in UCB

1.11

3.04

0.01

1188.58

0.044

Male gender in HAPLO

0.06

1.06

0.85

9.93

0.921

Age in UCB

 19–59

0.05

1.05

0.13

8.16

0.924

 > 60

0.19

1.21

0.11

12.86

0.803

Age in HAPLO

 19–59

0.56

1.76

1.38

24.32

0.441

 > 60

1.87

6.48

129.03

3297.48

0.024

Diagnosis in UCB: malignant disorder

0.44

1.55

0.07

31.99

0.338

Diagnosis in HAPLO: malignant disorder

1.23

3.41

8.04

114.50

0.070

ABO incompatibility in UCB

 No

−0.37

0.69

0.18

2.68

0.440

ABO incompatibility in HAPLO

 No

−0.66

0.52

0.49

5.75

0.293

Prophylaxis GvHD in UCB

 MTX+calcineurin inhibitor

−18.31

0.00

0.00

0.00

0.998

 Steroids+calcineurin inhibitor

−0.50

0.61

0.18

1.99

0.323

Conditioning regimen in HAPLO

 Reduced intensive

−0.46

0.63

0.23

15.27

0.665

 Myeloablative

−0.21

0.81

0.58

8.72

0.762

 Chronic GvHD in UCB (yes)

−18.22

0.00

0.00

0.00

0.997

 CMV in UCB (yes)

−0.58

0.56

0.19

1.67

0.186

 CMV in HAPLO (yes)

1.15

3.15

2.97

181.90

0.275

 LOS during HSCT in UCB

0.00

1.00

0.14

7.10

0.989

 LOS during HSCT in HAPLO

0.00

1.00

2.69

2.76

0.566

 LOS in the first year after HSCT in UCB

−0.01

0.99

0.14

6.88

0.165

 LOS in the first year after HSCT in HAPLO

0.01

1.01

2.72

2.76

0.080

 Relapse in UCB (yes)

0.92

2.52

0.02

348.06

0.219

 Relapse in HAPLO (yes)

0.21

1.24

0.74

16.06

0.787

 Cellularity (CD34+) in UCB

0.00

1.00

0.14

7.10

0.660

 Cellularity (CD34+) in HAPLO

0.00

1.00

2.72

2.72

0.590

 Mucositis in UCB (yes)

0.42

1.52

0.08

29.86

0.340

 Mucositis in HAPLO (yes)

0.17

1.19

1.00

10.75

0.779

 Acute GvHD in UCB (yes)

−1.12

0.32

0.17

0.61

0.014

 Acute GvHD in HAPLO (yes)

−0.23

0.79

0.58

8.34

0.730

  1. Abbreviations: CI, confidence interval; CMV reactivation, cytomegalovirus infection; GvHD, graft-versus host disease; HAPLO, haploidentical donors; HR, hazards ratio; HSCT, hematopoietic stem cell transplantation; LOS, length of hospital stay; MMF, mycophenolate mofetil; MTX, metothrexate; SOS, sinusoidal obstructive syndrome; TNC, total nucleated cell count; UCB, umbilical cord/placental blood. Bold values are significant associations (P<0.05).
Back to article page